Stoke Therapeutics, Inc. (STOK)
30.05
+0.24
(+0.81%)
USD |
NASDAQ |
Sep 08, 16:00
29.95
-0.10
(-0.33%)
Pre-Market: 08:35
Stoke Therapeutics Enterprise Value : 1.585B for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 1.585B |
| September 04, 2026 | 1.570B |
| September 03, 2026 | 1.581B |
| September 02, 2026 | 1.613B |
| September 01, 2026 | 1.637B |
| August 31, 2026 | 1.657B |
| August 28, 2026 | 1.683B |
| August 27, 2026 | 1.744B |
| August 26, 2026 | 1.775B |
| August 25, 2026 | 1.798B |
| August 24, 2026 | 1.727B |
| August 21, 2026 | 1.725B |
| August 20, 2026 | 1.669B |
| August 19, 2026 | 1.771B |
| August 18, 2026 | 1.715B |
| August 17, 2026 | 1.715B |
| August 14, 2026 | 1.661B |
| August 13, 2026 | 1.664B |
| August 12, 2026 | 1.767B |
| August 11, 2026 | 1.767B |
| August 10, 2026 | 1.721B |
| August 07, 2026 | 1.751B |
| August 06, 2026 | 1.702B |
| August 05, 2026 | 1.702B |
| August 04, 2026 | 1.686B |
| Date | Value |
|---|---|
| August 03, 2026 | 1.554B |
| July 31, 2026 | 1.511B |
| July 30, 2026 | 1.584B |
| July 29, 2026 | 1.549B |
| July 28, 2026 | 1.544B |
| July 27, 2026 | 1.539B |
| July 24, 2026 | 1.538B |
| July 23, 2026 | 1.560B |
| July 22, 2026 | 1.517B |
| July 21, 2026 | 1.508B |
| July 20, 2026 | 1.437B |
| July 17, 2026 | 1.523B |
| July 16, 2026 | 1.526B |
| July 15, 2026 | 1.576B |
| July 14, 2026 | 1.528B |
| July 13, 2026 | 1.548B |
| July 10, 2026 | 1.668B |
| July 09, 2026 | 1.759B |
| July 08, 2026 | 1.747B |
| July 07, 2026 | 1.770B |
| July 06, 2026 | 1.734B |
| July 02, 2026 | 1.750B |
| July 01, 2026 | 1.751B |
| June 30, 2026 | 1.752B |
| June 29, 2026 | 1.676B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biogen, Inc. | 38.46B |
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.62M |
| Revenue (Quarterly) | 9.325M |
| Total Expenses (Quarterly) | 70.94M |
| EPS Diluted (Quarterly) | -0.9334 |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | -660.8% |
| Earnings Yield | -11.22% |
| Normalized Earnings Yield | -11.22 |